These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 24686779)

  • 1. Three-dimensional histologic validation of high-resolution SPECT of antibody distributions within xenografts.
    Branderhorst W; Blezer EL; Houtkamp M; Ramakers RM; van den Brakel JH; Witteveen H; van der Have F; Gratama van Andel HA; Vastenhouw B; Wu C; Walsum MS; van Dongen GA; Viergever MA; Bleeker WK; Beekman FJ
    J Nucl Med; 2014 May; 55(5):830-7. PubMed ID: 24686779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
    Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
    J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
    Huhtala T; Laakkonen P; Sallinen H; Ylä-Herttuala S; Närvänen A
    Nucl Med Biol; 2010 Nov; 37(8):957-64. PubMed ID: 21055627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
    Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
    Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
    J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ⁹⁹mTc-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study.
    Li C; Wen B; Wang L; Feng H; Xia X; Ding Z; Gao B; Zhang Y; Lan X
    Nucl Med Commun; 2015 May; 36(5):452-60. PubMed ID: 25591074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.
    Goetz M; Ziebart A; Foersch S; Vieth M; Waldner MJ; Delaney P; Galle PR; Neurath MF; Kiesslich R
    Gastroenterology; 2010 Feb; 138(2):435-46. PubMed ID: 19852961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo.
    Bogdanov A; Kang HW; Querol M; Pretorius PH; Yudina A
    Bioconjug Chem; 2007; 18(4):1123-30. PubMed ID: 17508710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma.
    Sogawa C; Tsuji AB; Yoshida C; Inubushi M; Furukawa T; Koizumi M; Akahori Y; Ukai Y; Kurosawa G; Kurosawa Y; Saga T
    Nucl Med Commun; 2012 Jul; 33(7):719-25. PubMed ID: 22453549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
    Müller C; Fischer E; Behe M; Köster U; Dorrer H; Reber J; Haller S; Cohrs S; Blanc A; Grünberg J; Bunka M; Zhernosekov K; van der Meulen N; Johnston K; Türler A; Schibli R
    Nucl Med Biol; 2014 May; 41 Suppl():e58-65. PubMed ID: 24360901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.